Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Tuebingen – page 9

607 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
607
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

607 trials in Tuebingen

Open in trial search

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SAR444336
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neuroblastoma+3

Recruiting

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Gd2Il18Cart
  • Sponsor:Universitaet Muenster

Study of venetoclax, treosulfan and fludarabine before stem cell transplant in patients with acute myeloid leukemia and myelodysplastic syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treosulfan
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study of intestinal gel containing levodopa, carbidopa and entacapone to treat motor and behavioral symptoms in patients with Parkinson's disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Levodopa
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3372993
  • Sponsor:Washington University School Of Medicine

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION
  • Sponsor:Splicebio S.L.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on cutaneous lupus erythematosus and psoriatic arthritis, evaluating novel therapeutic approaches for managing chronic inflammatory conditions.

  • Lupus skin manifestations
  • Joint inflammation
  • Autoimmune responses

Studies aim to assess new treatment options for improving patient outcomes and quality of life.

02 Oncology Research

Comprehensive studies on various cancer types, including metastatic prostate cancer and basal cell carcinoma, exploring innovative treatment combinations.

  • Advanced cancer therapies
  • Pediatric liver tumors
  • Targeted treatments

Research focuses on improving survival rates and developing more effective treatment strategies.

03 Neurological Disorders

Groundbreaking research in multiple system atrophy and seizure disorders, investigating new therapeutic approaches for complex neurological conditions.

  • Brain function disorders
  • Movement disorders
  • Epilepsy management

Clinical trials aim to enhance treatment options for patients with challenging neurological conditions.

04 Ophthalmology Studies

Advanced research in eye disorders, including Leber congenital amaurosis and geographic atrophy, focusing on innovative treatment approaches.

  • Retinal diseases
  • Visual function
  • Gene therapy

Trials aim to preserve and improve vision in patients with rare and progressive eye conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.